Securities Purchase AgreementSecurities Purchase Agreement • February 21st, 2023 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (the “Agreement”), dated as of ________________, 2023, is by and among MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
KATALYST SECURITIES LLCMyMD Pharmaceuticals, Inc. • February 21st, 2023 • In vitro & in vivo diagnostic substances • New York
This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC (“Katalyst”), registered broker dealer and member of the Financial Industry Regulatory Authority (“FINRA”) and SIPC, by MyMD Pharmaceuticals, Inc., a publicly traded corporation duly organized under the laws of the State of New Jersey (the “Company”), to act as a non-exclusive placement agent (the “Placement Agent”) in connection with a registered direct offering pursuant to an effective “shelf” registration statement by the Company of its securities (the “Offering”). The Offering is currently anticipated to be a registered direct offering of (i) shares of the Company’s Series F Convertible Preferred Stock (the “Preferred Stock”), no par value (each, a “Share”) and (ii) warrants to purchase shares of the Company’s Common Stock with a term of five (5) years from the date of issuance (each, an “Warrant” and collectively with the Shares, the Warrants are sometimes herein r
